Byetta lawsuit claims, as well as cases filed over other incretin mimetics have been transferred to a federal litigation recently established in the Southern District of California, according to a recent court order.
Lawsuits involving Byetta, Januvia and similar medications part of this class of type-2 diabetes drugs allege pancreatitis, pancreatic cancer and thyroid cancer, and will be overseen by federal judge Anthony J. Battaglia. Court documents indicate that at least 53 cases had been filed in separate federal jurisdictions at the time a Transfer Order was issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on August 26th, 2013. Many of these claims include Byetta pancreatic cancer allegations.
Since being approved by the U.S. Food and Drug Administration (FDA) in 2005, Byetta has been involved in multiple warnings issued by the agency. After an alert linking Byetta to pancreatitis was issued in 2008, the FDA announced its investigation of incretin mimetics on March 14, 2013 in light of findings that the diabetes drugs may be associated with pre-cancerous cellular changes in the pancreas, a condition called pancreatic duct metaplasia.
Concerns were strengthened this past April when an analysis from the Institute of Safe Medicine Practices revealed the high prevalence of pancreatic cancer in individuals who took the medication. Over a 12-month period that ended in June 2012, 71 cases of Byetta pancreatic cancer were reported to the FDA via its database of adverse event reports, along with 263 pancreatitis reports and 14 instances of thyroid cancer. Despite these revelations, a Byetta recall has not been issued.
Cases filed in the newly-created federal multidistrict litigation of Byetta lawsuits and other cases involving incretin mimetics allege the manufacturers of these drugs failed to warn about their side effects.
Byetta and other incretin mimetics work to regulate the production of insulin in the pancreas by imitating the action of a hormone produced in the intestinal tract known as incretin. As the medical community continues to investigate the dangers of these medications, the number of Byetta and Januvia lawsuits is likely to rise.
With the recent consolidation of Januvia and Byetta lawsuits, the time is now to file a claim against the makers of the incretin mimetic that injured you. Join the growing number of individuals who are starting the process of filing cases against Byetta at .